Inhibrx Cash on Hand 2020-2022 | INBX
Inhibrx cash on hand from 2020 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Inhibrx Annual Cash on Hand
(Millions of US $) |
| 2021 |
$131 |
| 2020 |
$129 |
| 2019 |
$12 |
Inhibrx Quarterly Cash on Hand
(Millions of US $) |
| 2022-03-31 |
$143 |
| 2021-12-31 |
$131 |
| 2021-09-30 |
$113 |
| 2021-06-30 |
$126 |
| 2021-03-31 |
$108 |
| 2020-12-31 |
$129 |
| 2020-09-30 |
$128 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.533B |
$0.007B |
|
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
|
